GlassScriptPhysician profile
Katherine Duff
NPI 1053482950
$3,958.77
in general payments reported to CMS, 2019-2025
24 companies · $91.43 in 2025
The $91.43 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,279 · 2022: $1,257 · 2023: $1,267 · 2024: $63.83 · 2025: $91.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $894.36 | 2021-2022 | |
| Medtronic, INC. | $637.33 | 2022-2023 | Intellis Adaptivestim, Vanta Adaptivestim, Accurian |
| Abbott Laboratories | $630.96 | 2021-2024 | Proclaim, Eterna |
| Nevro Corp. | $385.55 | 2022-2023 | Senza |
| Ibsa Pharma INC. | $380.98 | 2021-2023 | Tirosint, Licart |
| Depuy Synthes Sales INC. | $168.56 | 2022-2025 | Orthovisc, Monovisc |
| Grt US Holding, INC. | $114.34 | 2022 | |
| Boston Scientific Corporation | $95.82 | 2021-2022 | |
| Abbvie INC. | $82.52 | 2022-2025 | |
| Pacira Therapeutics, INC. | $78.05 | 2021 | |
| Averitas Pharma INC. | $73.06 | 2023 | Qutenza |
| Biodelivery Sciences International, INC. | $57.37 | 2021 | |
| Collegium Pharmaceutical, INC. | $50.96 | 2021-2023 | Belbuca |
| Amgen INC. | $47.40 | 2021-2022 | |
| Lilly USA, LLC | $35.19 | 2021-2023 | Emgality, Reyvow |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $34.53 | 2022-2023 | Durolane |
| Amneal Pharmaceuticals LLC | $34.28 | 2023 | Lyvispah |
| Kowa Pharmaceuticals America, INC. | $28.48 | 2022-2023 | Seglentis |
| Lundbeck LLC | $27.03 | 2023 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $23.14 | 2022 | |
| Si-Bone, INC. | $22.97 | 2023 | |
| Pfizer INC. | $22.95 | 2023 | |
| Novo Nordisk INC | $19.49 | 2023 | Rybelsus |
| Merz Pharmaceuticals, LLC | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Duff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.